82
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE
“
MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS
”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
TECHNOLOGICAL DESIGN AND PRODUCTION FEATURES OF THE DOSAGE
FORM IN THE FORM OF CAPSULES OF ANTI-DIABETIC PHARMACOLOGICAL
AGENTS
Smail B.S.
1
Umirzakova U.N.
2
Torlanova B.O.
3
JSC "South Kazakhstan Medical Academy", Shymkent, Republic of Kazakhstan
e-mail: 19930101n@mail.ru
https://doi.org/10.5281/zenodo.17321390
Background:
Diabetes mellitus is one of the most common chronic, non-communicable
diseases of our time, affecting millions of people worldwide. According to the World Health
Organization, the number of patients with this disease increases annually, making the development
of effective and safe medications highly socially and medically important. The modern
pharmaceutical industry places particular emphasis on creating convenient, stable, and bioavailable
dosage forms of antidiabetic drugs.
Study Objective:
To develop and validate a technology for producing capsules containing an
antidiabetic pharmacological agent that ensures the stability of the active substance, high
bioavailability, and ease of use for patients.
Materials and Methods:
Subject of study: an antidiabetic drug (e.g., metformin or glimepiride)
as a model substance. Excipients: fillers (microcrystalline cellulose, lactose), lubricants and binders
(talc, starch), capsule shells (gelatin and HPMC capsules).
Results:
An optimal capsule composition was selected using excipients that improve powder
flowability and drug stability. An encapsulation technology was developed that ensures uniform
dosing and compliance with pharmacopoeial requirements. The stability of the resulting dosage form
under standard storage conditions was demonstrated. The resulting capsules are characterized by
controlled release of the active ingredient, which contributes to increased therapeutic efficacy.
Conclusions:
1. A technology for producing capsules containing an antidiabetic drug was
developed and experimentally validated. 2. The results demonstrate high stability, biopharmaceutical
acceptability, and ease of use of this dosage form. 3. The use of capsules increases the effectiveness
of antidiabetic therapy and improves patient compliance.
